Hims & Hers Health (NYSE:HIMS) shares are up 9% in early trading Monday, climbing from $28.82 to $31 and change as investors ...

Novo Nordisk has resolved its patent infringement lawsuit against telehealth provider Hims & Hers, entering into a collaboration to distribute Novo Nordisk’s weight loss medications through the Hims ...

Novo Nordisk is dropping its lawsuit against Hims & Hers Health, as it has reached an agreement with the telehealth company. The deal will permit Hims & Hers Health to sell Ozempic and Wegovy on its ...

COPENHAGEN, March 9 (Reuters) - Novo Nordisk said on Monday it will sell its blockbuster Wegovy and Ozempic drugs through the U.S. telehealth company Hims & Hers Health platform, ending a legal ...

Novo Nordisk is dismissing its patent infringement lawsuit against telehealth company Hims & Hers, as the two companies have reached an agreement that will see Novo Nordisk’s branded weight loss ...

The Novo Nordisk partnership legitimizes Hims & Hers’ business model by replacing compounded GLP-1 sales with branded Wegovy and Ozempic distribution. Hims generated $2.35B revenue in 2025 (+59% YoY) ...

Starting today, eligible customers can access a broad assortment of treatment options, including the only FDA-approved GLP-1 weight loss pill Based on an independent provider’s clinical decision, ...

Hims & Hers Health, Inc. (NYSE:HIMS) is one of the 11 Best Day Trading Stocks to Buy Now. Investment bank Barclays discussed Hims & Hers Health, Inc. (NYSE:HIMS)’s shares on March 11th. It raised the ...